Back to search

Switzerland· 69531002

Nintedanib Spirig HC 150 mg, Weichkapsel

A nintedanib product containing nintedanibum, registered in Switzerland by Spirig HealthCare AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L01EX09

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedNintedanib Spirig HC 150 mg, Weichkap…ATCL01EX09REGISTER NO.69531002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Nintedanib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX09 (nintedanib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Nintedanib · ATC L01EX09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nintedanib costs, country by country.

Normalised to the WHO defined daily dose (0.38 g), so markets compare like for like.

  • Switzerland: $34.12 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Nintedanib · price per daily dose (0.38 g)

USD · FX 28 Sept 2026

  • US United States$51.13 (acquisition cost)
  • CH Switzerland$34.12
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
nintedanibum
Manufacturer
Spirig HealthCare AG
Country
Switzerland (CH)
ATC code
L01EX09
ATC class
Nintedanib
Defined daily dose
0.38 g, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680695310023
    Blist 60 Stk
    CHF 665.4

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

160 interactions on record for nintedanib.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nintedanib · interactions on record

160 records

  • 21 severe
  • 139 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • DexamethasoneH02AB02severe
  • RifampicinJ04AB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nintedanib in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nintedanib products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Nintedanib Cipla, Nintedanib Ratiopharm
  • Belgium · Nintedanib Accordpharma, Nintedanib Eg
  • Cyprus · Nintedanib Teva
  • Czechia · Nintedanib Glenmark, Nintedanib Sandoz
  • Germany · Nintedanib, Nintedanib 1 A Pharma
  • Denmark · Nintedanib "sandoz", Nintedanib Glenmark
  • Estonia · Agarf, Nintedanib Sandoz
  • Spain · Nintedanib, Nintedanib Accordpharma
  • Finland · Nintedanib Glenmark, Nintedanib Ratiopharm
  • France · Nintedanib Arrow, Nintedanib Biogaran
  • United Kingdom (Northern Ireland) · Nintedanib, Nintedanib Accord Healthcare
  • Greece · Nifib, Nindraf
  • Croatia · Gevesla, Nintedanib Accordpharma
  • Hungary · Nintedanib Accordpharma, Nintedanib Onkogen
  • Ireland · Nintedanib Accordpharma, Nintedanib Clonmel
  • Iceland · Agarf, Nintedanib Accord
  • Italy · Nintedanib Accordpharma, Nintedanib Aurobindo
  • Liechtenstein · Nintedanib Accord, Nintedanib Viatris
  • Lithuania · Agarf, Nintedanib Sandoz
  • Luxembourg · Nintedanib Eg, Nintedanib Eurogenerics
  • Latvia · Agarf, Nintedanib Sandoz
  • Malta · Nifiden Adalvo, Nintedanib Adalvo
  • Netherlands · Gevesla, Nintedanair
  • Norway · Nintedanib Accord, Nintedanib Devatis
  • Poland · Nintedanib, Nintedanib Accordpharma
  • Portugal · Nintedanib Accordpharma, Nintedanib Eugia
  • Romania · Gevesla, Nintedanib Dr. Reddy’s
  • Sweden · Nintedanib Devatis, Nintedanib Glenmark
  • Slovenia · Nintedanib Accordpharma, Nintedanib Stada
  • Slovakia · Nintedanib Stada, Nintedanib Teva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d957ae11-adaf-4c66-a7a2-4bfaad3801f5
GET /v1/drugs/d957ae11-adaf-4c66-a7a2-4bfaad3801f5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "nintedanibum 150 mg",
  "valid_from": "2026-01-01",
  "limitations": "[{\"description\":\"<p>F&uuml;r alle verg&uuml;tungspflichtigen Indikationen gilt:<br>Kostengutsprache durch den Krankenversicherer nach vorg&auml;ngiger Konsultation des Vertrauensarztes im Rahmen der erstmaligen Indikationsstellung. F&uuml;r die Behandlung mit NINTEDANIB SPIRIG HC ist keine neue Kostengutsprache n&ouml;tig, wenn in derselben Indikation bereits eine Kostengutsprache f&uuml;r das Originalpr&auml;parat oder ein anderes Generikum besteht.</p>\",\"costApproval\":null,\"indication\":\"22044.XX\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"},{\"description\":\"<p><strong>IPF</strong><br>Diagnosestellung der idiopathischen Lungenfibrose (IPF) gem&auml;ss internationalen Empfehlungen (ATS/ERS) durch spezialisierte Zentren f&uuml;r IPF bzw. durch entsprechend qualifizierte Fach&auml;rzte f&uuml;r Pneumologie.</p>\\n<p>Folgender Indikationscode ist zu &uuml;bermitteln: 22044.01</p>\",\"costApproval\":null,\"indication\":\"22044.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"},{\"description\":\"<p><strong>PF-ILD</strong><br>Diagnosestellung von chronischen fibrosierenden interstitiellen Lungenerkrankungen (ILDs) mit einem progressiven Ph&auml;notyp gem&auml;ss internationalen Empfehlungen (ATS/ERS) durch spezialisierte Zentren f&uuml;r Pneumologie bzw. durch entsprechend qualifizierte Fach&auml;rzte f&uuml;r Pneumologie.</p>\\n<p>Eine Therapieweiterf&uuml;hrung kann durch spezialisierte Zentren f&uuml;r Pneumologie oder Rheumatologie bzw. durch entsprechend qualifizierte Fach&auml;rzte f&uuml;r Pneumologie oder Rheumatologie erfolgen.</p>\\n<p>Folgender Indikationscode ist zu &uuml;bermitteln: 22044.02</p>\",\"costApproval\":null,\"indication\":\"22044.02\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"},{\"description\":\"<p><strong>SSc-ILD</strong><br>Diagnosestellung der mit systemischer Sklerose assoziierten interstitiellen Lungenerkrankung (SSc-ILD) gem&auml;ss internationalen Empfehlungen (ATS/ERS/EULAR) durch spezialisierte Zentren f&uuml;r Pneumologie bzw. durch entsprechend qualifizierte Fach&auml;rzte f&uuml;r Pneumologie.</p>\\n<p>Eine Therapieweiterf&uuml;hrung kann durch spezialisierte Zentren f&uuml;r Pneumologie oder Rheumatologie bzw. durch entsprechend qualifizierte Fach&auml;rzte f&uuml;r Pneumologie oder Rheumatologie erfolgen.</p>\\n<p>Folgender Indikationscode ist zu &uuml;bermitteln: 22044.03</p>\",\"costApproval\":null,\"indication\":\"22044.03\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"}]",
  "galenic_form": "Weichkaps 150 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2026-01-01",
  "self_retention_pct": 10
}

See everything about nintedanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.